Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on "Dr.
Reddy's announces the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg in the U.S. Market".
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code: RDY)
| DR. REDDY'S LABORATORIES LTD. | CONTACT | |
| 8-2-337, Road No. 3, Banjara Hills, | Investor relationS | Media relationS |
| Hyderabad - 500034. Telangana, India. | Saunak SAVLA saunaks@drreddys.com (Ph: +91-40-49002135) | Calvin Printer calvinprinter@drreddys.com (Ph: +91-40- 49002121) |
announces the launch of Esomeprazole Magnesium
Delayed-Release Capsules USP, 20 mg in the U.S. Market
Hyderabad, India and Princeton, NJ, USA. July 20, 2018- Dr.
Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr.
Reddy's") today announced the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, an over-the-counter
(OTC) therapeutic equivalent generic version of Nexium 24HR Capsules in the United States market as approved by
the U.S. Food and Drug Administration (USFDA).
Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, is an
OTC proton pump inhibitor used to treat frequent heartburn occurring two or more days a week in adults*.
"This launch continues to demonstrate our deep R&D and
manufacturing capabilities to bring newer store-brand OTC medications to the market," says Milan Kalawadia, Vice President
and Head, US OTC and Speciality Rx businesses, Dr. Reddy's Laboratories. "We look forward to collaborating with our
customers to provide high-quality, affordable alternatives to consumers."
The combined market of Nexium 24HR Capsules and
private label OTC Esomeprazole Magnesium products had U.S. sales of approximately $311 million for the most recent twelve months
ending in May 2018 according to IRI .
Dr. Reddy's Esomeprazole Magnesium Delayed-Release Capsules
USP, 20 mg is available in 14 count bottles sold in cartons of 1, 2, or 3 bottles each. Each bottle contains a complete 14-day
course of treatment. Use only as directed.
*May take 1 to 4 days for full effect. IRI Latest
52 wks. period ending May 2018
Nexium is a registered trademark of AstraZeneca
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd.
(BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics
and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical
services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,
diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets
include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the
words "may", "will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements
due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency
exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and
in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration
The company assumes no obligation to update any information contained